Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials

被引:54
作者
Le Tourneau, Christophe [1 ,2 ,3 ]
Kamal, Maud [1 ,2 ]
Tsimberidou, Apostolia-Maria [4 ]
Bedard, Philippe [5 ]
Pierron, Gaelle [6 ]
Callens, Celine [6 ]
Rouleau, Etienne [6 ]
Vincent-Salomon, Anne [7 ]
Servant, Nicolas [8 ]
Alt, Marie [1 ,2 ]
Rouzier, Roman [3 ,9 ,10 ]
Paoletti, Xavier [8 ]
Delattre, Olivier [11 ]
Bieche, Ivan [6 ,12 ]
机构
[1] Inst Curie, Dept Med Oncol, Paris, France
[2] Inst Curie, Dept Med Oncol, 35 Rue Dailly, F-92210 St Cloud, France
[3] Versailles St Quentin En Yvelines Univ, EA7285, Versailles, France
[4] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[5] Princess Margaret Hosp, Dept Med Oncol & Hematol, Drug Dev Program, Toronto, ON M4X 1K9, Canada
[6] Inst Curie, Dept Genet, Paris, France
[7] Inst Curie, Dept Pathol, Paris, France
[8] Inst Curie, INSERM, U900, Paris, France
[9] Inst Curie, Dept Surg, Paris, France
[10] Inst Curie, Dept Surg, F-92210 St Cloud, France
[11] Inst Curie, INSERM, U830, Paris, France
[12] Univ Paris 05, EA7331, Paris, France
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2016年 / 108卷 / 04期
关键词
METASTATIC BREAST-CANCER; PROOF-OF-CONCEPT; PERSONALIZED MEDICINE; CONVENTIONAL THERAPY; PHASE-II; HETEROGENEITY; SHIVA; DNA; MULTICENTER; EVOLUTION;
D O I
10.1093/jnci/djv362
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the advent of high-throughput molecular technologies, several precision medicine (PM) studies are currently ongoing that include molecular screening programs and PM clinical trials. Molecular profiling programs establish the molecular profile of patients' tumors with the aim to guide therapy based on identified molecular alterations. The aim of prospective PM clinical trials is to assess the clinical utility of tumor molecular profiling and to determine whether treatment selection based on molecular alterations produces superior outcomes compared with unselected treatment. These trials use treatment algorithms to assign patients to specific targeted therapies based on tumor molecular alterations. These algorithms should be governed by fixed rules to ensure standardization and reproducibility. Here, we summarize key molecular, biological, and technical criteria that, in our view, should be addressed when establishing treatment algorithms based on tumor molecular profiling for PM trials.
引用
收藏
页数:10
相关论文
共 44 条
[1]   Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) [J].
Andre, Fabrice ;
Bachelot, Thomas ;
Commo, Frederic ;
Campone, Mario ;
Arnedos, Monica ;
Dieras, Veronique ;
Lacroix-Triki, Magali ;
Lacroix, Ludovic ;
Cohen, Pascale ;
Gentien, David ;
Adelaide, Jose ;
Dalenc, Florence ;
Goncalves, Anthony ;
Levy, Christelle ;
Ferrero, Jean-Marc ;
Bonneterre, Jacques ;
Lefeuvre, Claudia ;
Jimenez, Marta ;
Filleron, Thomas ;
Bonnefoi, Herve .
LANCET ONCOLOGY, 2014, 15 (03) :267-274
[2]   Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation [J].
Bennett, Nigel C. ;
Farah, Camile S. .
CANCERS, 2014, 6 (04) :2296-2312
[3]   Haplo-insufficiency: a driving force in cancer [J].
Berger, Alice H. ;
Pandolfi, Pier Paolo .
JOURNAL OF PATHOLOGY, 2011, 223 (02) :137-146
[4]   Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data [J].
Boeva, Valentina ;
Popova, Tatiana ;
Lienard, Maxime ;
Toffoli, Sebastien ;
Kamal, Maud ;
Le Tourneau, Christophe ;
Gentien, David ;
Servant, Nicolas ;
Gestraud, Pierre ;
Frio, Thomas Rio ;
Hupe, Philippe ;
Barillot, Emmanuel ;
Laes, Jean-Francois .
BIOINFORMATICS, 2014, 30 (24) :3443-3450
[5]   MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma [J].
Bourdeaut, Franck ;
Grison, Camille ;
Maurage, Claude-Alain ;
Laquerriere, Annie ;
Vasiljevic, Alexandre ;
Delisle, Marie-Bernadette ;
Michalak, Sophie ;
Figarella-Branger, Dominique ;
Doz, Francois ;
Richer, Wilfrid ;
Pierron, Gaelle ;
Miquel, Catherine ;
Delattre, Olivier ;
Couturier, Jerome .
CANCER GENETICS, 2013, 206 (04) :124-129
[6]   Absolute quantification of somatic DNA alterations in human cancer [J].
Carter, Scott L. ;
Cibulskis, Kristian ;
Helman, Elena ;
McKenna, Aaron ;
Shen, Hui ;
Zack, Travis ;
Laird, Peter W. ;
Onofrio, Robert C. ;
Winckler, Wendy ;
Weir, Barbara A. ;
Beroukhim, Rameen ;
Pellman, David ;
Levine, Douglas A. ;
Lander, Eric S. ;
Meyerson, Matthew ;
Getz, Gad .
NATURE BIOTECHNOLOGY, 2012, 30 (05) :413-+
[7]   Emerging landscape of oncogenic signatures across human cancers [J].
Ciriello, Giovanni ;
Miller, Martin L. ;
Aksoy, Buelent Arman ;
Senbabaoglu, Yasin ;
Schultz, Nikolaus ;
Sander, Chris .
NATURE GENETICS, 2013, 45 (10) :1127-U247
[8]   First FDA Authorization for Next-Generation Sequencer [J].
Collins, Francis S. ;
Hamburg, Margaret A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25) :2369-2371
[9]   Guidance for laboratories performing molecular pathology for cancer patients [J].
Cree, Ian A. ;
Deans, Zandra ;
Ligtenberg, Marjolijn J. L. ;
Normanno, Nicola ;
Edsjo, Anders ;
Rouleau, Etienne ;
Sole, Francesc ;
Thunnissen, Erik ;
Timens, Wim ;
Schuuring, Ed ;
Dequeker, Elisabeth ;
Murray, Samuel ;
Dietel, Manfred ;
Groenen, Patricia ;
Van Krieken, J. Han .
JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (11) :923-931
[10]   Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe [J].
Dubbink, Hendrikus J. ;
Deans, Zandra C. ;
Tops, Bastiaan B. J. ;
van Kemenade, Folkert J. ;
Koljenovic, S. ;
van Krieken, Han J. M. ;
Blokx, Willeke A. M. ;
Dinjens, Winand N. M. ;
Groenen, Patricia J. T. A. .
MOLECULAR ONCOLOGY, 2014, 8 (04) :830-839